2024
Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis
Zeydan B, Azevedo C, Makhani N, Cohen M, Tutuncu M, Thouvenot E, Siva A, Okuda D, Kantarci O, Lebrun-Frenay C. Early Disease-Modifying Treatments for Presymptomatic Multiple Sclerosis. CNS Drugs 2024, 1-11. PMID: 39285136, DOI: 10.1007/s40263-024-01117-9.Peer-Reviewed Original ResearchRadiologically isolated syndromeRisk factorsLaboratory biomarkersMultiple sclerosisDisease-modifying treatmentsSpinal cordGadolinium-enhancing lesionsEfficacy of disease-modifying treatmentsRandomized clinical trialsIncrease diagnostic accuracyLack of clinical guidelinesSymptomatic MSNeurofilament-light chainCSF abnormalitiesPresymptomatic individualsAdverse eventsMale sexMS criteriaClinical eventsDiagnostic accuracyClinical trialsDisease outcomeClinical guidelinesYounger ageLesions
2020
Treatment Considerations in the Radiologically Isolated Syndrome
Makhani N. Treatment Considerations in the Radiologically Isolated Syndrome. Current Treatment Options In Neurology 2020, 22: 3. PMID: 32009206, DOI: 10.1007/s11940-020-0608-8.Peer-Reviewed Original ResearchClinical intervention trialsMultiple sclerosisIntervention trialsClinical neurological symptomsFirst clinical eventDisease-modifying therapiesDisease-modifying treatmentsIsolated SyndromeNeurological eventsNeurological symptomsClinical eventsClinical trialsRecent FindingsIndividualsTreatment considerationsTherapeutic interventionsAccurate diagnosisBeneficial effectsTrialsSclerosisSuch interventionsSyndromeSubsequent developmentDiagnosisInterventionTherapy